Why the Smallpox Vaccine Succeeded: Key Advantages Over Variolation and Quarantine

The smallpox vaccine was the decisive tool in global eradication. Its superiority over earlier methods (variolation, quarantine) stemmed from six critical advantages:

1. High effectiveness: ~95% protective efficacy in vaccinated individuals, far exceeding variolation.
2. Safety: Used vaccinia virus (related to cowpox), not live smallpox. Variolation carried a 1–2% mortality rate; vaccine serious adverse events were rare.
3. Long-lasting immunity: Protection persisted for decades, often lifelong.
4. Cost-effectiveness: Cheap to produce and distribute, enabling mass global campaigns.
5. Ease of administration: Simple skin puncture (bifurcated needle) required minimal training, facilitating rapid, large-scale vaccination.
6. No transmission risk: Vaccinia does not spread smallpox; variolation could inadvertently spark outbreaks.

These factors combined to make the vaccine the foundation of the WHO's successful 1967–1980 eradication campaign—the only human disease eradicated to date.